30 closest matches · ranked by relevance
Acute Respiratory Failure
Primary: The Primary Outcome Variable for This Study Will be the Short Form of the Continuous Scale Physical Functional Performance Test (CS-PFP) Called the PFP-10 — 19.0; 20.9…
Myotonia · Non-Dystrophic Myotonia
Primary: Patient-reported Stiffness on the IVR — 2.53; 4.21; 1.60; 5.27 units on a scale — p=<0.001
Charcot Marie Tooth Disease
Primary: Number of Participants With a Decrease in Cramp Duration — 2; 0 participants
Intensive Care Unit · Muscle Weakness
Primary: Lower Extremity Strength, at Hospital Discharge, of 3 Bilateral Muscle Groups (Pretibial, Triceps Surae, and Quadriceps) Measured Via MMT Using a Composite Medical…
Duchenne Muscular Dystrophy
Primary: Number of Subjects With an Adverse Event. — 1; 0; 0; 0 participants
Chronic Obstructive Pulmonary Disease
Primary: Exercise Capacity — 465.5; 462.7 meters — p=<0.05
Multiple Sclerosis
Primary: Walking Endurance — 42; 25 meters
Intermittent Claudication · Peripheral Vascular Disease
Primary: Change From Baseline in Initial Walking Distance — 64.3 metres
GNE Myopathy
Primary: Mean Area Under the Curve (AUClast) of Plasma ManNAc (Baseline-adjusted) — 7461; 9432 hr*ng/mL
Obstructive Sleep Apnea · Amyotrophic Lateral Sclerosis · Muscular Dystrophies
Primary: Proof of Diagnostic Consistency — 95.7; 78.1; 90 % agreement
Neurofibromatosis 1
Primary: Mitochondrial Respiration Efficiency (as Measured by OCR). — 67.7167; 53.7000; 73.3358; 68.5789 picomole/minute — p=<0.01
Neuromuscular Disease
Primary: Urine 15-F2t Isoprostane Concentration — 2.7; 2.6 ng/mg Cr — p=0.88
Acute Respiratory Distress Syndrome
Primary: Hospital Mortality to Day 90 — 288; 289; 213; 216 Participants — p=0.93
Brain Diseases, Metabolic, Inborn · Urea Cycle Disorder · Ornithine Transcarbamylase Deficiency
Primary: Concentration of Glutamine and Myoinositol by MRS — 4.97; 3.66; 3.78; 4.50 mM — p=0.003
Neuromuscular Diseases
Primary: Change From Baseline Vital Capacity at One Year. — 33.33; -7.41 percentage of Change of vital capacity — p=<0.001
Muscle Weakness
Primary: Percent Change in the Amplitude of Evoked Compound Muscle Action Potential by Electromyography Between the First to Fifth Response — 0 percent change
Muscle Relaxation
Primary: Train of Four 0,9 (90%) — 49.9; 41.7 minutes
Amyotrophic Lateral Sclerosis (ALS) · Neuromuscular Diseases
Primary: Percent Change in Maximal Inspiratory Pressure (MIP) — 0.3; -3.1; -4.8; -5.0 percentage change in MIP from baseline
Muscular Dystrophies · Duchenne Muscular Dystrophy · Becker Muscular Dystrophy
Primary: Muscle, Nerve, or Vascular Damage — 16 participants
Peripheral Neuropathy · Diabetes
Primary: Body Mass Index (BMI) — 30.7 kg/m^2
Duchenne Muscular Dystrophy · Spinal Muscular Atrophy · Congenital Muscular Dystrophy
Primary: Geometric Mean Titer Ratio for Each Vaccine Strain — 3.76; 3.53; 2; 1.46 geometric mean titer ratio — p=<.05
Heart Failure
Primary: Maximal Voluntary Quadriceps Force [% Change From Baseline] — -30; -5 percentage change
Parkinson's Disease · Multiple Sclerosis
Primary: Maximum Expiratory Pressure (MEP) — 78.6; 75.56; 99.00; 99.38 cm H2O — p=0.899
Heart Failure
Primary: Baseline Heart Rate Recovery — 32.5; 30.4 beats per minute
ICU Acquired Weakness
Primary: Peak Acceleration Measured in Extensor Carpi Radialis Longus — 0.476; 1.639; 0.541; 1.608 units of Gravity
Intensive Care (ICU) Myopathy
Primary: Duration of Intubation — 10.22 days
Chronic Venous Disease · Venous Insufficiency · Deep Venous Obstruction
Primary: Percentage Change of Haemodynamic Flow — 34.8; 62.8; 9; 14.8 % change
Inclusion Body Myositis
Primary: Count of Adverse Events Reported — 109; 52 adverse events reported
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
Duchenne Muscular Dystrophy
Primary: Percent Change in Range of Motion From Baseline to 180 Days — 67; 33 percentage of change